Basel, 01 November 2017 Roche to present new data across a range of blood diseases at the American Society of Hematology (ASH) 2017 Annual Meeting Further results from emicizumab phase III studies in people with haemophilia A with inhibitors will be featured New data for polatuzumab vedotin in a difficult-to-treat blood cancer, which led to... Read more
Basel, 01 November 2017 Roche to present new data across a range of blood diseases at the American Society of Hematology (ASH) 2017 Annual Meeting Further results from emicizumab phase III studies in people with haemophilia A with inhibitors will be featured New data for polatuzumab vedotin in a difficult-to-treat blood cancer, which led to... Read more
Basel, 31 October 2017 New data suggest Roche’s etrolizumab can provide clinically meaningful improvements in the treatment of two of the most common forms of inflammatory bowel disease Roche presents etrolizumab data in Crohn’s disease and ulcerative colitis at UEGW Data suggest etrolizumab leads to endoscopic improvement associated with early symptomatic remission in Crohn’s disease... Read more
Basel, 27 October 2017 New OCREVUS (ocrelizumab) data at ECTRIMS advance clinical understanding of underlying progression in multiple sclerosis Data show superiority of OCREVUS compared to Rebif (interferon beta-1a) in significantly reducing disability Progression Independent of Relapse Activity (PIRA) in people with relapsing multiple sclerosis (RMS) Data demonstrates first method to automatically detect and characterise... Read more
26 October 2017 FDA accepts Roche’s supplemental Biologics License Application for Avastin as a front-line treatment for women with advanced ovarian cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for Avastin® (bevacizumab) in combination with chemotherapy (carboplatin... Read more
Basel, 24 October 2017 Roche recognised as a global leader for sustainable water management Sustainability is an integral part of Roche’s business strategy The company’s goal is to reduce water consumption by 10% per employee by 2020 For the first time, Roche (SIX: RO, ROG; OTCQX: RHHBY) has been identified as a global leader for... Read more
Basel, 16 October 2017 Roche to present new OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive forms of multiple sclerosis at ECTRIMS Largest body of OCREVUS data presented at a congress to date reinforce favourable benefit-risk profile and advance clinical understanding of disease progression Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today... Read more
Basel, 16 October 2017 Roche to present new OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive forms of multiple sclerosis at ECTRIMS Largest body of OCREVUS data presented at a congress to date reinforce favourable benefit-risk profile and advance clinical understanding of disease progression Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today... Read more
Basel, 13 October 2017 CHMP recommends EU approval of Roche’s Alecensa (alectinib) as a first-line treatment for people with ALK-positive NSCLC Positive opinion based on phase III results showing Alecensa reduced the risk of disease progression or death by more than half versus crizotinib Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European... Read more
Basel, 06 October 2017 FDA approves Roche cobas Zika as first commercially-available donor screening test for Zika virus Zika virus infection is linked to neurological complications in adults, and brain defects in fetuses and newborn infants cobas Zika complements efforts to prevent the spread of Zika virus through blood donations in the U.S. cobas Zika... Read more